List view / Grid view
Dr. Elias A. Zerhouni (born April 12, 1951) is an Algerian-born American physician scientist radiologist and biomedical engineer. As a world-renowned national and international leader, Zerhouni is widely viewed as one of the leading authorities on emerging trends and issues in biomedical sciences and medical care. He spent much of his career on the faculty of the Johns Hopkins University school of Medicine.
From 1995 to 2002, he served as Executive Vice-Dean of Johns Hopkins School of Medicine and, in 2002, was appointed by President George W. Bush and confirmed by the Senate as the 15th Director of the National Institutes of Health, serving until 2008. In 2009, under the Obama Administration, he served as one of the country’s first presidential science envoys to foster scientific and technologic collaboration with other nations.
He also served as a senior fellow for the Bill and Melinda Gates foundation from 2009 through 2010. Since 2011, he is the President for Global Research and Development at Sanofi, one of the largest multinational pharmaceutical companies in the world.
Sanofi and Regeneron Pharmaceuticals, Inc. have announced that the EC…
Sanofi and Regeneron Pharmaceuticals, Inc. have announced that the EC has granted marketing authorisation for Dupixent for use in adults with moderate-to-severe atopic dermatitis...
The European Commission (EC) has granted marketing authorisation for Regeneron…
The European Commission (EC) has granted marketing authorisation for Regeneron and Sanofi’s Kevzara (sarilumab) for the treatment of rheumatoid arthritis...
The EMA is a world class regulator, whose scientific recommendations…
16 May 2017 | By European Federation of Pharmaceutical Industries and Associations (EFPIA)
The EMA is a world class regulator, whose scientific recommendations are a vital element of the ongoing effort to provide EU citizens with quality medicines
The European Medicine Agency's CHMP has adopted a positive opinion…
28 April 2017 | By Niamh Marriott, Junior Editor
The European Medicine Agency's CHMP has adopted a positive opinion for the marketing authorisation of Sanofi and Regeneron Pharmaceuticals’ Kevzara...
Suliqua is an innovative new combination therapy that has the…
19 January 2017 | By Niamh Marriott, Digital Editor
Suliqua is an innovative new combination therapy that has the potential to address significant unmet needs for people living with type 2 diabetes in Europe
Soliqua 100/33 is the combination of Lantus (insulin glargine 100…
29 November 2016 | By Niamh Louise Marriott, Digital Editor
Soliqua 100/33 is the combination of Lantus (insulin glargine 100 Units/mL) and lixisenatide, a GLP-1 receptor agonist, studied in a Phase 3 program...
Sanofi and Regeneron have announced that a one-year Phase III study…
6 June 2016 | By Victoria White, Digital Content Producer
Sanofi and Regeneron have announced that a one-year Phase III study evaluating investigational dupilumab met its primary and key secondary endpoints.
The FDA's EMDAC has recommended the approval of the NDA…
26 May 2016 | By Victoria White, Digital Content Producer
The FDA's EMDAC has recommended the approval of the NDA for the fixed-ratio combination of insulin glargine and lixisenatide...
Sanofi and Regeneron have announced positive topline results from two…
1 April 2016 | By Victoria White
Sanofi and Regeneron have announced positive topline results from two placebo-controlled Phase III studies evaluating investigational dupilumab in adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD).
The fixed-ratio combination of insulin glargine and lixisenatide, a GLP-1…
14 September 2015 | By Victoria White
The fixed-ratio combination of insulin glargine and lixisenatide, a GLP-1 receptor agonist, demonstrated statistically superior reduction in HbA1c compared with insulin glargine alone...
Sanofi announced today that the LixiLan-O Phase III clinical trial…
29 July 2015 | By Victoria White
Sanofi announced today that the LixiLan-O Phase III clinical trial met its primary objective in patients with type 2 diabetes treated with metformin...
Sanofi announce top-line results of the Phase IIIb ELIXA cardiovascular…
19 March 2015 | By Victoria White
Sanofi announce top-line results of the Phase IIIb ELIXA cardiovascular outcomes study, comparing lixisenatide to placebo in adults with type 2 diabetes...
Sanofi (EURONEXT : SAN and NYSE : SNY) and Regeneron…
10 July 2014 | By Sanofi
Sanofi (EURONEXT : SAN and NYSE : SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema.
Sanofi and UCB announce they have entered into a scientific…
11 March 2014 | By Sanofi
Sanofi and UCB announce they have entered into a scientific and strategic collaboration for the discovery and development of innovative anti-inflammatory small molecules...
Goal is to identify novel active compounds to accelerate the…
15 January 2014 | By Sanofi
Goal is to identify novel active compounds to accelerate the discovery and development of new antibiotics...
